Mus musculus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA182084 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Defining a molecular roadmap of cellular reprogramming into iPS cells [miRNA profiling]
| PRJNA182085 | ENA
Project description:Defining a molecular roadmap of cellular reprogramming into iPS Cells [DNA methylation]
| PRJNA193330 | ENA
Project description:Defining a molecular roadmap of cellular reprogramming into iPS cells [ChIP-Seq]
| PRJNA182086 | ENA
Project description:Defining a molecular roadmap of cellular reprogramming into iPS cells
| PRJNA182083 | ENA
Project description:Mouse B cells, upon ectopic expression of the transcription factor C/EBPalpha for 18h, can be reprogrammed to induced pluripotent stem (iPS) cells with extremely high efficiency. To understand the molecular control of this phenomenon we performed a time course proteomic analysis by label-free protein quantification of proteins during B cell reprogramming to iPS cells.
2016-02-24 | PXD002769 | Pride
Project description:RNY1 is strongly expressed in cytoplasm during early iPS reprogramming phase (d0-3) but, underlying molecular mechanisms of RNY1 remain unknown during iPS reprogramming.
2018-09-30 | GSE118887 | GEO
Project description:Clinical application of induced pluripotent stem (iPS) cells is limited by low efficiency of iPS derivation, and protocols that permanently modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPS cells towards clinically useful cell types are lacking. Here we describe a simple, non-mutagenic strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate anti-viral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem (RiPS) cells into terminally differentiated myogenic cells. Our method represents a safe, efficient strategy for somatic cell reprogramming and directing cell fates that has broad applicability for basic research, disease modeling and regenerative medicine. We isolated RNA from human RNA derived iPS cells, viral derived iPS cells, different human fibroblasts and human embryonic stem cells for hybridization to the Affymetrix gene expression microarrays.
2010-09-30 | E-GEOD-23583 | biostudies-arrayexpress
Project description:Full pluripotency of induced pluripotent stem (iPS) cells has been determined as viable all-iPS mice can be generated through tetraploid complementation. Subsequently, activation of imprinted Dlk-Dio3 gene cluster has been suggested to correlate with the pluripotency of iPS cells1. However, evidence from recent studies has demonstrated that loss of imprinting at the Dlk-Dio3 locus did not correlate strictly with the reduced pluripotency of iPS cells. Therefore, it becomes indispensable to exploit other reliable molecular markers for evaluating the quality of iPS cells accurately. In the present study, we successfully utilize the sequential reprogramming approach and produce all-iPS mice to six generations using iPS cell lines derived from different cell lineages which contain the same proviral integration in the genome. By comparing the global gene expression and epigenetic modifications of both "tetra-on" and corresponding "tetra-off" iPS cell lines established from either mesenchymal or hematopoietic lineages through deep sequencing analysis of mRNA expression, small RNA profiling, histone modifications (H3K4m2, H3K4me3 and H3K27me3) and DNA methylation, very few differences are detected among all the iPS cell lines investigated. However, we find that two imprinted genes, disruption of which correlate with the reduced pluripotency of iPS cells. Therefore, our data not only provide the first demonstration that producing of all-iPS mice to six generations is feasible, but reveal that two imprinted regions can be served as pluripotency markers of iPS cells. Examination of the mRNA expression in 13 cell types
2013-12-06 | E-GEOD-36290 | biostudies-arrayexpress
Project description:Noncoding RNA transcriptome analysis during cellular reprogramming
| PRJNA239218 | ENA
Project description:Clinical application of induced pluripotent stem (iPS) cells is limited by low efficiency of iPS derivation, and protocols that permanently modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPS cells towards clinically useful cell types are lacking. Here we describe a simple, non-mutagenic strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate anti-viral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem (RiPS) cells into terminally differentiated myogenic cells. Our method represents a safe, efficient strategy for somatic cell reprogramming and directing cell fates that has broad applicability for basic research, disease modeling and regenerative medicine.
2010-09-30 | GSE23583 | GEO